Covenant Metabolic Specialists LLC — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$1,366,346	454
2024	Research	$235,426	67
2023	Research	$109,345	18

Breakdown

Who paid Research payments · program years 2023–2025

Madrigal Pharmaceuticals $1,402,941 407 payments
Gilead Sciences, Inc. $186,111 104 payments
Takeda Pharmaceuticals U.S.A., Inc. $117,960 26 payments
Genentech, Inc. $4,106 2 payments

Studies the money was for Research payments · program years 2023–2025

A Phase 3 Multinational Doubleblind Randomized Placebocontrolled Study of Mgl3196 Resmetirom in Patients With Nonalcoholic Steatohepatitis Nash and Fibrosis to Resolve Nash and Reduce Progression to Cirrhosis Andor Hepatic Decompensation $869,484 214 payments
A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) $340,652 105 payments
A 52Week Phase 3 Openlabel Extension Study With A Doubleblind Leadin to Evaluate Safety and Biomarkers of Resmetirom Mgl3196 in Patients With Nonalcoholic Fatty Liver Disease Nafld Maestronafldopenlabelextension Maestronafldole $192,804 88 payments
A Multicenter, Single-arm, Open-label, Phase 1b Study to Explore the Mechanism of Action and Evaluate the Safety of Ontamalimab in Participants With Nonalcoholic Steatohepatiti s With Fibrosis Stages 2 Through 4 $105,239 16 payments
The study explores the Mechanism of Action and Evaluates the Safety of Ontamalimab in Participants with Nonalcoholic Steatohepatitis with Fibrosis Stages 2 through 4 $12,721 10 payments
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis $11,500 1 payment
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis $11,500 1 payment
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) $11,050 1 payment
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis $10,039 1 payment
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) $9,500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.